Back to top

Latest News

person with MS using cane
26 April 2018

A renewed call for fully funding the NDIS.

MS Australia today joins other disability peak organisations such as NDS, Every Australian Counts and PWDA, in calling for more information as to how the...

Image of white pills
20 April 2018

PBS listing for MAVENCLAD® (cladribine tablets) for RRMS not recommended by PBAC

The Pharmaceutical Benefits Advisory Committee (PBAC) announced at 4pm today (20/4/18), they have not recommended the listing of MAVENCLAD® (cladribine tablets) for relapsing remitting MS (RRMS) on the Pharmaceutical Benefits Scheme (PBS).

The PBAC said that it, “did not recommend the...

World MS Day 2018
19 April 2018

World MS Day 2018 - six weeks away!

Exciting news from the Multiple Sclerosis International Federation (MSIF)!

Overnight, MSIF launched this year’s World MS Day #bringinguscloser campaign, with the theme of Research. 
A highlight of the campaign is a clever animation on how new...
advance care planning week
16 April 2018

MS Australia marks Advance Care Planning Week – 16-22 April 2018

If you couldn’t speak for yourself, who would you want to speak on your behalf?

What decisions about your healthcare would you want them to make?

Planning medical care in advance regardless of your age or health is really important, and particularly so if you have a chronic illness...

Biogen image
16 March 2018

ZINBRYTA (daclizumab) voluntary withdrawal – Federal Department of Health/TGA statement

Please talk to your neurologist if you are on Zinbryta.

Further to our 5/3/18 news report on the withdrawal of ZINBRYTA (daclizumab), the Department of Health/TGA issued a statement on 15 March 2018, with extra information for the public, health professionals and neurologists...

Photo of Deidre Mackechnie
8 March 2018

MS Australia CEO, Deidre Mackechnie, celebrates International Women's Day 2018

International Women’s Day provides a worldwide focus on gender disparity.  But also gives us a day to celebrate the contribution of all women and to acknowledge the challenges faced by many.

For more than 17,000 women living in Australia that challenge is Multiple Sclerosis.


5 March 2018

ZINBRYTA (daclizumab) voluntary withdrawal

As reported in various media outlets over the weekend, pharmaceutical companies Biogen and AbbVie have announced the voluntary worldwide withdrawal for ZINBRYTA ® (daclizumab) for Relapsing multiple sclerosis.

As stated in the official media release (link below), patients currently...

Rare Voices
27 February 2018

Rare Disease Day - Wednesday 28th February 2018

The annual Rare Disease Day raises global awareness about rare diseases and their impact. The theme this year is research.
For the majority of rare diseases, there is no cure and many go undiagnosed.
Whilst Multiple Sclerosis (MS) is relatively...
1 February 2018

Ocrevus™ (ocrelizumab) for RRMS - Federal Government approves PBS listing

The Federal Government today announced the listing of Ocrevus (ocrelizumab) for relapsing remitting MS (RRMS) on the Pharmaceutical Benefits Scheme (PBS).

In 2017, Ocrevus was registered for use in Australia by the...

medicinal cannabis
11 January 2018

Medicinal Cannabis and Multiple Sclerosis – What does it all mean for me?

Considering the progress made in both legislation and availability of medicinal cannabis and its derived products over the last year, we would like to provide some guidance to anyone affected by MS to help in navigating this sticky subject.

Firstly, some background:...

2017 2018
22 December 2017

Celebrating 2017 and looking to 2018...

A Message from the Chief Executive of Multiple Sclerosis Australia Deidre Mackechnie:

As we wrap up another year and many of us look forward to festivities and holidays, I want to take this opportunity, on behalf of the team at Multiple Sclerosis...

19 December 2017

PBAC outcomes for Ocrevus™ (ocrelizumab) for PPMS and MAVENCLAD (cladribine tablets) for RRMS

The Pharmaceutical Benefits Advisory Committee (PBAC) makes recommendations about the medicines for subsidy through the Pharmaceutical Benefits Scheme (PBS).

On Friday 15th December 2017, the PBAC announced they have not recommended...